ALNY Stock Forecast 2025-2026
Distance to ALNY Price Targets
ALNY Price Momentum
🤔 Considering Alnylam (ALNY)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest ALNY Stock Price Targets & Analyst Predictions
Based on our analysis of 43 Wall Street analysts, ALNY has a bullish consensus with a median price target of $301.60 (ranging from $195.00 to $500.00). The overall analyst rating is Buy (7.9/10). Currently trading at $241.76, the median forecast implies a 24.8% upside. This outlook is supported by 22 Buy, 9 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 106.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALNY Analyst Ratings
ALNY Price Target Range
Latest ALNY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALNY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $280.00 |
| Feb 26, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $310.00 |
| Feb 26, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $300.00 |
| Feb 26, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $320.00 |
| Feb 25, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $500.00 |
| Feb 24, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $500.00 |
| Feb 18, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $385.00 |
| Feb 14, 2025 | Morgan Stanley | Michael Ulz | Equal-Weight | Maintains | $284.00 |
| Feb 14, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $320.00 |
| Feb 14, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $300.00 |
| Feb 11, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $300.00 |
| Jan 21, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $300.00 |
| Jan 13, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $400.00 |
| Jan 13, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $320.00 |
| Jan 7, 2025 | Bernstein | William Pickering | Outperform | Maintains | $310.00 |
| Nov 18, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $296.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $400.00 |
| Nov 12, 2024 | Wolfe Research | Andy Chen | Underperform | Downgrade | $0.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $400.00 |
| Nov 1, 2024 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $310.00 |
Alnylam Pharmaceuticals Inc. (ALNY) Competitors
The following stocks are similar to Alnylam based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alnylam Pharmaceuticals Inc. (ALNY) Financial Data
Alnylam Pharmaceuticals Inc. has a market capitalization of $31.24B with a P/E ratio of 0.0x. The company generates $2.25B in trailing twelve-month revenue with a -12.4% profit margin.
Revenue growth is +34.9% quarter-over-quarter, while maintaining an operating margin of -17.7% and return on equity of -414.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Alnylam Pharmaceuticals Inc. (ALNY) Business Model
About Alnylam Pharmaceuticals Inc.
Develops RNA interference therapeutics for diseases.
Alnylam Pharmaceuticals generates revenue through the development and commercialization of RNAi therapeutics aimed at treating various genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases. The company collaborates with other organizations to enhance its research capabilities and expand its therapeutic pipeline, which is critical for driving sales and market adoption of its innovative treatments.
Located in Cambridge, Massachusetts, Alnylam is recognized as a leader in the biotechnology sector, focusing on transforming patient care through cutting-edge gene therapies. The company is actively engaged in partnerships that support its mission to redefine treatment approaches for complex medical conditions, which positions it well within the evolving landscape of genetic therapeutics.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2,230
CEO
Dr. Yvonne L. Greenstreet M.B.A., MBChB
Country
United States
IPO Year
2004
Website
www.alnylam.comAlnylam Pharmaceuticals Inc. (ALNY) Latest News & Analysis
Alnylam Pharmaceuticals will present a company overview at the Stifel 2025 Virtual CNS Forum on March 18, 2025, at 3:00 pm ET, with a live webcast available on their website.
Alnylam Pharmaceuticals' upcoming presentation at a major forum highlights potential developments in RNAi therapeutics, which could impact stock performance and investor sentiment.
Alnylam Pharmaceuticals announced the retirement of Dr. Phillip A. Sharp from its Board of Directors, effective May 8, 2025. He co-founded the company in 2002 and will continue as an advisor.
Dr. Phillip A. Sharp’s retirement from Alnylam’s Board could impact investor confidence, given his significant role in the company's foundation and strategic direction in RNAi therapeutics.
Alnylam Pharmaceuticals is hosting an R&D Day to showcase progress in its RNAi therapeutics pipeline, highlighting near- and mid-stage therapies with potential blockbuster opportunities.
Alnylam's R&D Day highlights significant pipeline advancements, indicating potential blockbuster therapies that could enhance revenue and market position, attracting investor interest.
Alnylam Delivers a Big Q4 Earnings Beat
1 month agoAlnylam Pharmaceuticals reported Q4 non-GAAP EPS of $0.06, outperforming analysts' expectations of a $0.60 loss.
Alnylam's unexpected profit indicates strong performance and potential growth, likely boosting investor confidence and affecting stock valuation positively.
Alnylam Pharmaceuticals will hold its Q4 2024 earnings conference call on February 13, 2025, at 8:30 AM ET, featuring key executives and analysts from major financial firms.
Alnylam Pharmaceuticals' Q4 earnings call indicates financial performance and strategic insights, influencing stock valuations and investor sentiment regarding future growth potential.
Alnylam Pharmaceuticals reported Q4 and full-year 2024 revenues of over $1.6 billion, a 33% increase from 2023, driven by strong performance in hATTR-PN and Rare diseases.
Alnylam's 33% revenue growth signals strong demand for its RNAi therapeutics, indicating robust business performance and potential for future profitability, which can influence stock valuation positively.
Frequently Asked Questions About ALNY Stock
What is Alnylam Pharmaceuticals Inc.'s (ALNY) stock forecast for 2025?
Based on our analysis of 43 Wall Street analysts, Alnylam Pharmaceuticals Inc. (ALNY) has a median price target of $301.60. The highest price target is $500.00 and the lowest is $195.00.
Is ALNY stock a good investment in 2025?
According to current analyst ratings, ALNY has 22 Buy ratings, 9 Hold ratings, and 1 Sell ratings. The stock is currently trading at $241.76. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALNY stock?
Wall Street analysts predict ALNY stock could reach $301.60 in the next 12 months. This represents a 24.8% increase from the current price of $241.76. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alnylam Pharmaceuticals Inc.'s business model?
Alnylam Pharmaceuticals generates revenue through the development and commercialization of RNAi therapeutics aimed at treating various genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases. The company collaborates with other organizations to enhance its research capabilities and expand its therapeutic pipeline, which is critical for driving sales and market adoption of its innovative treatments.
What is the highest forecasted price for ALNY Alnylam Pharmaceuticals Inc.?
The highest price target for ALNY is $500.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 106.8% increase from the current price of $241.76.
What is the lowest forecasted price for ALNY Alnylam Pharmaceuticals Inc.?
The lowest price target for ALNY is $195.00 from at , which represents a -19.3% decrease from the current price of $241.76.
What is the overall ALNY consensus from analysts for Alnylam Pharmaceuticals Inc.?
The overall analyst consensus for ALNY is bullish. Out of 43 Wall Street analysts, 22 rate it as Buy, 9 as Hold, and 1 as Sell, with a median price target of $301.60.
How accurate are ALNY stock price projections?
Stock price projections, including those for Alnylam Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
